Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study of LY4515100 in Healthy Male Participants
Sponsor: Eli Lilly and Company
Summary
The main purpose of this study is to evaluate how the body handles \[¹⁴C\]-LY4515100. The study will investigate how much \[¹⁴C\]-LY4515100 enters the bloodstream from the stomach or intestines and is available to have an effect on the body, how the body changes \[¹⁴C\]-LY4515100 so that it can be used or removed, and how the body gets rid of \[¹⁴C\]-LY4515100. For each participant, the study will last about 9 weeks and will include a Clinical Research Unit (CRU) stay lasting between 10 and 30 days.
Official title: A Phase 1, Open-Label, 2-Part Study of the Absorption, Metabolism, Excretion, and Bioavailability of [¹⁴C]-LY4515100 in Healthy Male Participants
Key Details
Gender
MALE
Age Range
18 Years - 55 Years
Study Type
INTERVENTIONAL
Enrollment
16
Start Date
2026-10
Completion Date
2026-12
Last Updated
2026-10-09
Healthy Volunteers
Yes
Conditions
Interventions
[¹⁴C]-LY4515100 Oral Solution
\[¹⁴C\]-LY4515100 administered orally
LY4515100 Tablet
LY4515100 administered orally
[¹⁴C]-LY4515100 IV
\[¹⁴C\]-LY4515100 administered IV
Locations (1)
Fortrea Clinical Research Unit
Madison, Wisconsin, United States